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Low molecular mass chondroitin sulfate suppresses 
chronic unpredictable mild stress-induced depression-like 
behavior in mice
The present study is aimed at testing the antidepressant-
-like effects and probable mechanisms of action of low mo-
lecular mass chondroitin sulfate (LMMCS) on depression 
induced by chronic unpredictable mild stress (CUMS) in 
mice. Four weeks of CUMS exposure resulted in depres-
sive-like behavior, expressed by a significant decrease in 
the locomotor activity and sucrose consumption and in-
creased immobility time in the forced swim test. Further, 
there was a significant reduction of 5-HT level in the hip-
pocampus region of depressed mice. Treatment of mice for 
four weeks with LMMCS ameliorated significantly both the 
behavioral and biochemical changes induced by CUMS. 
These novel results suggest that LMMCS produces an anti-
depressant-like effect in mice subjected to CUMS, which 
might be related, at least in part, to the increase of 5-HT 
concentration in the hippocampus. 
Keywords: low molecular mass chondroitin sulfate, chronic 
unpredictable mild stress, depression, mice, hippocampus, 
5-HT
As a common mood disorder, depression is often characterized by several key symp-
toms such as anhedonia, despair, hopelessness and memory impairment. In clinics, many 
antidepressants have been used to treat depression. Among them, selective serotonin 
reuptake inhibitors (SSRIs), like fluoxetine, remain the first-line antidepressants for major 
depressions (1). However, most of these drugs are limited by certain negative features, 
such as delayed efficacy (4–8 weeks) and noticeable side effects (1, 2). Moreover, studies 
have reported that only 22–40 % of patients benefit from drug treatment (3). It is therefore 
necessary to seek more effective drugs with fewer side effects and better tolerability.
Chondroitin sulfate (CS), a natural glycosaminoglycan (GAG), exists in the extracel-
lular matrix (ECM) or on the surface of animal cells. In the central nervous system (CNS), 
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epilepsy, stroke and Alzheimer’s disease (4), but it might also be involved in some biological 
activities such as neuroprotection, since it exerts protective effects on Aβ-induced damage 
in mouse hippocampus (5). Previous studies have demonstrated that low molecular mass 
GAGs, including low molecular mass chondroitin sulfate (LMMCS, molecular mass is 
about 3500–5300 Da), could cross the blood-brain barrier (6). 
In the present study, we investigated the influence of chronic treatment with LMMCS 
on behavioral and neurochemical changes induced by chronic unpredictable mild stress 
(CUMS) protocol in mice, as an animal model of depressive-like behaviors.
EXPERIMENTAL
Animals
Seventy-two male Kunming (Swiss) mice (18–24 g, 4 weeks old) were purchased from 
the Laboratory Animal Centre, Qingdao Food and Drug Inspection Institute (Qingdao, 
China). They were kept in standard plastic cages (six mice per cage) and maintained in a 
12-h light/dark cycle at room temperature 23–25 ° C and humidity 55 ± 5 %. Normative 
laboratory food and water were freely available, except during experimental procedures. 
Animals were acclimatized to the laboratory conditions for at least one week prior to use. 
They were then randomly allocated to one of six groups (n = 12/group) for behavioral tests 
(see below).
All procedures involving animals were carried out in compliance with the National 
Institutes of Health and institutional guidelines for the humane care of animals and were 
approved by the Animal Care Committee of Qingdao University (Qingdao, China).
Drugs and treatment
LMMCS was obtained from Qingdao Belt Biological Technology Co., Ltd. (China). 
Fluoxetine hydrochloride was purchased from Sigma (USA).
After adaptation to the cages for seven days, the mice were subjected to the baseline 
behavioral testing [open field test (OFT), sucrose preference test (SPT) and forced swim-
ming test (FST)]. They were then divided into six groups based on their baseline FST re-
sults (to make the average immobility time equal for each group): control group (C) and 
CUMS model group (CUMS) were given vehicle (deionized distilled water), LMMCS 
groups (CS) were administered 30, 100, and 300 mg kg–1 bm of LMMCS, resp., and fluox-
etine group (Flu 20) received 20 mg kg–1 bm of fluoxetine. 
Both LMMCS and fluoxetine were dissolved in deionized distilled water. In all ex-
periments, LMMCS, fluoxetine or vehicle were administered intragastrically (i.g.) 1 h prior 
to stress exposure. The mice were weighed every day and the doses were adjusted to their 
weight gain.
The procedural sequence is given in Fig. 1: (i) adaptation: one week, (ii) baseline be-
havioral tests (pre-tests for OFT, SPT, and FST, resp.): four days (every test takes one or two 
days), (iii) CUMS and LMMCS treatment: four weeks, (iv) post behavioral tests (OFT, SPT, 
and FST, resp.): four days, (v) brain tissue isolation.
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Chronic unpredictable mild stress procedure
The CUMS procedure was performed as described previously, with a slight modifica-
tion (7). All groups of animals, except for the control group, were exposed to CUMS. In 
brief, the CUMS protocol consisted of sequential application of a variety of mild stressors: 
fasting for 24 h, water deprivation for 24 h, cage tilting for 7 h, swimming (cold water 4 °C, 
5 min), behavior restriction for 2 h, light-dark-cycle reversal (12 h/12 h), finally, 1 h with an 
empty bottle; damp bedding for 24 h, foreign object for 24 h. To prevent habituation and to 
ensure unpredictability of the stressors, all stressors were randomly scheduled over a one 
week period and were continued for the duration of the experiment (Table I). Mice were 
subjected to one or two of the stressors (in random order) on one day and without repeti-
tive stressors on the two consecutive days. Control animals were isolated in a separate 
room and had no contact with the stressed animals.
Open field test
The open field test (OFT) is a measure of spatial exploration behavior of mice (total 
distance and entries in the center zone: horizontal movement scores reflect range of mo-
tion, rearing number: vertical movement scores reflect exploratory behaviors), as previ-
ously described (8). The open-field apparatus, a four-sided organic plastic square chamber 
(40 × 40 × 40 cm) with a dark floor, was divided into 16 equal squares by white lines. Each 
mouse was gently put in the center square. The first 60 seconds was set for adaptation. The 
OFT (the number of locomotion and rearing frequency) were observed for 5 min (Sony 
SSC-G218 camera located 190–200 cm above the arena, Sony, Japan) and were automati-
cally calculated by the ANY-maze video tracking system (SMART, Panlab SL, Spain). The 
cage was entirely cleaned with alcohol and dried to exclude potential interaction of the 
dejections in the trail. The value for each group was calculated as a percentage of the post-
test value relative to the mean pre-test value.
Sucrose preference test
Briefly, the mice were trained to adapt to 1 % (m/V) sucrose solution 24 h before testing 
(7). In the test phase, mice were able to access both tap water and a 1 % sucrose solution for 
24 h. The position of the two bottles (left/right sides of the cage) was changed randomly in 
order to avoid place preference. The sucrose preference value was calculated as a percent-
age of the volume of the consumed 1 % sucrose solution relative to the total volume of 
liquid intake.
Fig. 1. Schematic representation of the experimental design. OFT – open field test, SPT – sucrose 
preference test, FST – forced swimming test, CUMS - chronic unpredictable mild stress, LMMCS – 
low molecular mass chondroitin sulfate.
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Forced swimming test
The forced swimming test (FST) was carried out following the protocol of Porsolt et al. 
(9). The mice were placed in clear glass cylinders (40 cm tall × 18 cm diameter) filled with 
water (25 °C), approximately 23 cm deep, to prevent their tails from touching the bottom. 
Immobility was recorded during the total 4 min testing period. Mice were considered to 
be immobile when they made only small movements necessary to float and keep their 
Table I. Schedule for the chronic unpredictable mild stress procedure
Week Day Stress protocol Duration
1
Sun Foreign object 24 h
Mon Fasting and water deprivation 24 h
Tue Cage tilting 7 h
Wed Overnight illumination / empty bottle 12 h/1 h
Thu Cold water swimming 5 min
Fri Behavior restriction 2 h
Sat Damp bedding 24 h
2
Sun Overnight illumination / empty bottle 12 h/1 h
Mon Cage tilting 7 h
Tue Cold water swimming 5 min
Wed Fasting and water deprivation 24 h
Thu Behavior restriction 2 h
Fri Damp bedding 24 h
Sat Foreign object 24 h
3
Sun Cold water swimming 5 min
Mon Overnight illumination / empty bottle 12 h/1 h
Tue Fasting and water deprivation 24 h
Wed Behavior restriction 2 h
Thu Foreign object 24 h
Fri Cage tilting 7 h
Sat Damp bedding 24 h
4
Sun Fasting and water deprivation 24 h
Mon Cage tilting 7 h
Tue Overnight illumination / empty bottle 12 h/1 h
Wed Foreign object 24 h
Thu Damp bedding 24 h
Fri Cold water swimming 5 min
Sat Fasting and water deprivation 24 h
Mice were exposed to the stressors according to this schedule for four weeks. At the same time, animals were 
treated with LMMCS (30, 100 and 300 mg kg–1 bm) and fluoxetine (20 mg kg–1 bm) or vehicle intragastrically. 
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heads above the water surface. Test sessions were recorded with a video camera and the 
duration of immobility was scored using a video-computerized tracking system (SMART, 
Panlab SL).
Brain tissue sample preparation
The mice were sacrificed by decapitation after completion of the behavioral tests. The 
hippocampus was quickly isolated from the mice brain on ice, weighed and frozen in liq-
uid nitrogen and transported to –80 °C until assays were performed. 
ELISA assay for 5-HT
Hippocampus of one mouse from each group was homogenized in ice-cold buffer. 
The homogenates were centrifuged at 10000×g for 10 min at 4 °C and the supernatants were 
collected for further analysis. The supernatants were assayed using a serotonin ELISA kit 
(Abcam, UK) according to the manufacturer’s protocol and quantified with a microplate 
reader (450 nm). The results were shown as nanograms per gram of tissue.
Western blot for 5-HT1A receptor
Hippocampus of two mice from each group was homogenized in an ice-cold RIPA 
buffer (Solarbio, China), and centrifuged at 12000×g for 10 min at 4 °C. The supernatants 
were collected. Protein concentration was determined by a BCA (bicinchoninic acid) pro-
tein assay using bovine serum albumin as a standard. The proteins were separated with 
the aid of sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to a 
polyvinylidene difluoride membrane. After blocking in 3 % bovine serum albumin/Tris 
buffered saline with Tween 20 (TBST) at room temperature for 2 h, the membranes were 
incubated with the primary antibody at 4 °C overnight (anti-5HT1A 1:1000, Abcam, UK). 
After washing with TBST three times, the membranes were incubated with HRP conju-
gated anti-rabbit or anti-mouse lgG secondary antibodies (1:10000, Proteintech, USA) for 1 
h at room temperature. The blots were washed again three times with TBST buffer, and the 
immunoreactive bands were detected using a chemiluminescence system (Bio-Rad Chem-
iDox XRS, USA). Protein band densities were quantified using the Image J software (Bio-
Rad ChemiDoc XRS) while GAPDH (1:5000, Proteintech) was used as a loading control.
Statistical analysis
All data were normally distributed and are presented as mean ± standard error of the 
mean (SEM). The data were analyzed by One-way ANOVA, followed by Dunett’s (in the 
case of SPT and 5-HT tests) or Newman-Keuls (in the case of OFT and FST tests) multiple 
comparison post hoc test. A value of p < 0.05 was considered significant.
RESULTS AND DISCUSSION
LMMCS improved range of motion and exploratory aspiration 
In the OFT, horizontal scores reflect the range of motion including two parameters: 
total traveled distance and entries in the center zone; vertical scores reflect exploratory 
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aspiration (expressed as the total rearing number). In line with the decrease in the locomo-
tor activity induced by CUMS reported in previous studies (10), the horizontal and vertical 
scores of mice in the CUMS group (total traveled distance: 48.3 ± 4.6 %, p < 0.05, entries in 
center zone: 59.1 ± 5.8 %, p < 0.05, total rearing number: 48.4 ± 5.2 %, p < 0.01, Fig. 2) were 
reduced significantly compared to the control group (total traveled distance: 79.8 ± 7.0 %, 
entries in center zone: 134.2 ± 10.7 %, total rearing number: 120.3 ± 15.9 %, Fig. 2). 
Repeated LMMCS 300 mg kg–1 bm treatments reversed significantly these reduced 
scores (total traveled distance: 78.6 ± 4.9 %, p < 0.05, entries in center zone: 113.3 ± 16.6 %, 
Fig. 2. Effects of LMMCS administration on OFT: a) total traveled distance in the chamber, b) entries 
in the center zone, c) total rearing numbers in the chamber. Data are represented as mean ± SEM, n = 
8–10 mice per group. Statistically significant difference vs. CUMS group: * p < 0.05, ** p < 0.01, *** p < 







X.-M. Si et al.: Low molecular mass chondroitin sulfate suppresses chronic unpredictable mild stress-induced depression-like behavior 
in mice, Acta Pharm. 68 (2018) 361–371.
 
p < 0.05, total rearing number: 114.2 ± 21.1 %, p < 0.05, Fig. 2). However, neither 30 nor 100 
mg kg–1 bm showed a significant difference compared to the CUMS group for any param-
eter (Fig. 2). Fluoxetine at 20 mg kg–1 bm reversed all measured parameters (total traveled 
distance: 126.7 ± 7.5 %, p < 0.05, entries in center zone: 162.0 ± 23.9 %, p < 0.001, total rearing 
number: 109.1 ± 15.6 % p < 0.001, Fig. 2) compared to the CUMS group (Fig. 2). Taken to-
gether, these results suggest that repeated treatment with LMMCS could improve the 
range of motion and exploratory activity in mice subjected to the CUMS protocol. Interest-
ingly, our OFT results also revealed that the number of entries in the center zone showed 
significant differences between LMMCS treated and untreated groups, indicating that 
LMMCS could also improve the symptom of anxiety accompanied with depression (11).
LMMCS improved anhedonia 
To evaluate the effect of LMMCS on improving anhedonia, SPT was carried out. As 
shown in Fig. 3, the post hoc test analysis showed that a four-week CUMS exposure decreased 
significantly the percentage of sucrose consumption in the CUMS mice (53.4 ± 3.8 %, p < 0.01) 
compared to the control group (76.3 ± 5.4 %). Furthermore, the four-week treatment with 
LMMCS (100 mg kg–1 bm) increased the sucrose preference compared to the CUMS mice 
(71.1 ± 5.4 %, p < 0.05), and similarly to the fluoxetine-treated group (67.4 ± 5.1 %, p < 0.05). 
However, the other two doses did not change sucrose consumption compared to the CUMS 
group. These results suggest that LMMCS treatment could improve anhedonia-like status 
in the CUMS mice.
LMMCS reduced the immobility time in FST
The four-week exposure to CUMS increased the immobility time significantly when 
mice were subjected to the forced swimming test (131.08 ± 7.97 s, p < 0.05, compared to 
control mice, Fig. 4). Chronic LMMCS (30 and 100 mg kg–1 bm) or fluoxetine treatment re-
duced significantly the immobility time as a measure of helplessness and despair com-
pared to CUMS mice (LMMCS 30 mg kg–1: 83.07 ± 10.61 s, p < 0.05; LMMCS 100 mg kg–1:79.62 
± 11.71 s, p < 0.05; fluoxetine 20 mg kg–1: 73.02 ± 15.54 s, p < 0.05; Fig. 4). However, the LMMCS 
300 mg kg–1 treatment showed no significant change compared to the CUMS group. These 
Fig. 3. Effects of LMMCS administration on the sucrose preference in the SPT. Data are represented 
as mean ± SEM from 9-12 mice per group. Statistically significant difference vs. CUMS group: * p < 
0.05, ** p < 0.01. C – control, CS – LMMCS, CUMS – chronic unpredictable mild stress, Flu – fluoxetine.
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results are in line with the results obtained in OFT and SPT, suggesting an antidepressant-
like effect of LMMCS. 
LMMCS reversed 5-HT concentration in the hippocampus region of mice 
5-HT levels in the hippocampus correlate closely with depression (12). Our ELISA assay 
results revealed that 5-HT concentration decreased significantly in the hippocampus region 
of mice exposed to four weeks of CUMS compared to the control group (76.62 ± 5.42 ng g–1, 
p < 0.01, Fig. 5). The four-week treatment with LMMCS (100 and 300 mg kg–1 bm) or fluoxetine 
increased significantly the 5-HT concentration in the hippocampus region compared to the 
CUMS group (LMMCS 100 mg kg–1: 112.03 ± 11.18 ng g–1, p < 0.05; LMMCS 300 mg kg–1: 
125.11 ± 6.57 ng g–1, p < 0.01, fluoxetine 20 mg kg–1: 126.68 ± 4.82 ng g–1, p < 0.001), except for 
the lowest dose of 30 mg kg–1 bm, suggesting that LMMCS could increase the 5-HT level 
in the hippocampus of depressed mice.
Fig. 4. Effects of LMMCS administration on the immobility time in the FST. Data are represented as 
mean ± SEM from 9–12 mice per group. Statistically significant difference vs. CUMS group: * p < 0.05. 
C – control, CS – LMMCS, CUMS – chronic unpredictable mild stress, Flu – fluoxetine.
Fig. 5. Effects of LMMCS administration on the 5-HT level in the hippocampus region of mice. Data 
are represented as mean ± SEM (n = 8–10). Statistically significant difference vs. CUMS group: * p < 0.05, 
** p < 0.01, *** p < 0.001. C – control, CS – LMMCS, CUMS – chronic unpredictable mild stress, Flu – 
fluoxetine.
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LMMCS did not change the 5-HT1A protein expression in the hippocampus region  
of mice
Brain 5-HT1A autoreceptor is important to maintain the 5-HT level in synapse, control-
ling 5-HT release by a negative feedback mechanism (12). To elucidate the possible pri-
mary mechanism of 5-HT increase in the hippocampus, the Western blot was conducted 
for the 5-HT1A receptor expression. As shown in Fig. 6, the CUMS group did not show any 
change in the 5-HT1A receptor expression compared to the control group. Although the 
5-HT1A receptor expression slightly increased in LMMCS (100 and 300 mg kg
–1 bm) or 
fluoxetine-treated groups compared to the CUMS group, these were not significant, thus 
indicating that the 5-HT1A receptor might not be involved in the antidepressant-like effect 
of LMMCS. In contrast, a recent report mentioned that the 5-HT1A receptor expression in 
the hippocampus of CUMS mice was reduced compared to the control group (13). Conse-
quently, we suppose that two possibilities could explain the above result. First, the CUMS 
procedure in our study may not be strong enough to change the expression of the t5-HT1A 
receptor in the hippocampus of tested mice. Second, the 5-HT level decrease in the hip-
pocampus may be a consequence of other receptors’ interplay or signaling pathways like 
the brain derived neurotrophic factor (BDNF), since several studies suggested that 5-HT 
can stimulate the BDNF gene or protein expression in depressive patients (14) and rodents 
(15). Further studies are therefore necessary to elucidate this issue. 
Fig. 6. Effects of LMMCS administration on the 5-HT1A receptor expression in the hippocampus re-
gion of mice. Data are represented as mean ± SEM (n = 3). C – control, CS – LMMCS, CUMS – chronic 
unpredictable mild stress, Flu–fluoxetine.
CONCLUSIONS
In the present study, a four-week LMMCS treatment improved significantly the de-
pressive-like behaviors of CUMS mice, and increased 5-HT levels in the hippocampus. 
These novel findings suggest possible benefits of LMMCS application in depression treat-
ment. However, further experiments that would provide more precise information about 
the potential antidepressant effect of LMMCS are warranted.
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Abbreviations, acronyms, symbols. – BDNF – brain-derived neurotrophic factor, ELISA – enzyme-
linked immune sorbent assay, Flu 20 – fluoxetine group, CS – chondroitin sulfate, CUMS – chronic 
unpredictable mild stress, ECM – extracellular matrix, FST – forced swimming test, GAG – glycos-
aminoglycan, HRP – horseradish peroxidase, 5-HT – serotonin, LMMCS – low molecular mass chon-
droitin sulfate, OFT – open field test, SPT – sucrose preference test, SSRIs – selective serotonin reup-
take inhibitors, TBST – Tris buffered saline with Tween 20.
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